Advances in individualization and precision in immunotherapy for triple-negative breast cancer
YAN Yuxin
ZHANG Jian
Abstract：The treatment strategies for triple negative breast cancer(TNBC)are constantly being updated and are gradually moving into the era of immunotherapy.Immune checkpoint inhibitor(ICI)has been proven to have significant tumor growth inhibitory effects in a variety of malignant tumors,but the benefit population of single-agent immunotherapy for breast cancer is minimal.Currently,the research of TNBC immunotherapy mainly focuses on the combination regimen(including chemotherapy combination,targeted combination,radiotherapy combination,etc.)and the exploration of the dominant population.A series of clinical studies have been carried out on ICI in combination with other therapeutic methods,and the results of the relevant studies have been cited and recommended by domestic and international guidelines.This article outlines the clinical development and latest progress of TNBC immunotherapy,aiming to deeply explore the individualization and precision of immunotherapy for triple-negative breast cancer,to provide the basis for clinical treatment of breast cancer.
Keywords：Triple negative breast cancerImmunotherapyIndividualization and precisionCombination therapy
Publication Date：2024-10-20
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 429-433 )